Radium-223 dichloride for treating metastatic hormone relapsed prostate cancer with bone metastases (ID576) Single Technology Appraisal


As part of the NICE’s single technology appraisal process, this assessment aims at critically reviewing the manufacturer’s submission related to the evidence for the clinical and cost-effectiveness of radium-223 dichloride (trade name Xofigo) for the treatment of metastatic castration resistant prostate cancer.  The submission focuses on an international, multicentre, double-blind phase three randomised controlled trial (RCT) sponsored by the manufacturer.  Evidence from a smaller phase-two, international multicentre, double-blind RCT are presented in a supportive role.


Craig Ramsay; c.r.ramsay@abdn.ac.uk


Completed; for further information see: http://www.nets.nihr.ac.uk/projects/hta/125701